Systemic Sclerosis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Systemic Sclerosis Emerging Therapy and TPP Insights

Thelansis’s “Systemic Sclerosis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Systemic Sclerosis Overview

Systemic sclerosis is a complex autoimmune disease characterized by microvascular injury, immune dysregulation, and progressive fibrosis affecting the skin and internal organs. Pulmonary complications, particularly interstitial lung disease and pulmonary hypertension, are major drivers of morbidity and mortality. Historically, treatment has been organized around individual organ manifestations, combining immunosuppressive, vasodilator, and supportive therapies. Therapeutic advances have improved management of SSc-associated ILD: nintedanib slows pulmonary-function decline, while tocilizumab is approved to slow pulmonary-function decline in adults with SSc-ILD. However, these therapies do not reverse established fibrosis or provide comprehensive control across organ systems. This unmet need is driving development of deeper immune-targeting and antifibrotic strategies, including CD19-directed CAR-T therapies, T-cell–engaging bispecifics, and other approaches aimed at disrupting pathogenic immune and fibrotic pathways. Multiple CAR-T programs are now in clinical development, while early reports of skin remodeling and organ stabilization remain investigational. For stakeholders, SSc represents an important frontier in rare immunology: moving from organ-specific control toward durable, multisystem disease modification.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)